RxNorm April 2021 Release

RxNorm April 2021 Release. NLM Tech Bull. 2021 Mar-Apr;(439):b5.

The RxNorm April monthly release became available for download on Monday, April 5, 2021 and includes a new Qualitative Distinction modifier. See below for more details. 

RXNORM DATA CHANGES

New Qualitative Distinction

Qualitative Distinction (QD) modifiers allow flexibility in the RxNorm model to create a new RxNorm Concept Unique Identifier (RXCUI) or differentiate an existing medication concept when needed. The new QD modifier "PMDD" distinguishes products indicated for the treatment of premenstrual dysphoric disorder (PMDD).

The April 2021 release includes the new "PMDD" QD for the following active concepts:

RXCUI              TTY       String

2532159          SCD      PMDD fluoxetine 10 MG Oral Tablet

647555            SBD      PMDD fluoxetine 10 MG Oral Tablet [Sarafem]

803293            SCD      PMDD fluoxetine 15 MG Oral Tablet

803295            SBD      PMDD fluoxetine 15 MG Oral Tablet [Sarafem]

2532163          SCD      PMDD fluoxetine 20 MG Oral Tablet

647556            SBD      PMDD fluoxetine 20 MG Oral Tablet [Sarafem]

For each SCD or SBD with a QD, there is an associated attribute in RXNSAT with the attribute name (ATN) of 'RXN_QUALITATIVE_DISTINCTION.' The April release contains the following new attribute value (ATV) to match the QD strings found in the SCD and SBD normalized names:

• PMDD

RELATED NEWS

Did you know that RxClass includes Med-RT content, such as drugs that "may_treat" the DISEASE class COVID-19? Explore the RxClass browser by entering "COVID-19" in the RxClass browser search bar, clicking "COVID-19" under "DISEASE," then click on a class hierarchy to see content.

Learn more about RxClass and other web-based drug information resources on the RxNav landing page.